Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome
- 21 June 2010
- journal article
- Published by Wiley in Bipolar Disorders
- Vol. 12 (4), 404-413
- https://doi.org/10.1111/j.1399-5618.2010.00823.x
Abstract
Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome.Bipolar Disord 2010: 12: 404–413. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S. Objective: The present study examined the relationship between medical burden in bipolar disorder and several indicators of illness severity and outcome. It was hypothesized that illnesses of the endocrine/metabolic system would be associated with greater psychiatric symptom burden and would impact the response to treatment with lithium and valproate. Methods: Data were analyzed from two studies evaluating lithium and valproate for rapid-cycling presentations of bipolar I and II disorder. General medical comorbidity was assessed by the Cumulative Illness Rating Scale (CIRS). Descriptive statistics and logistic regression analyses were conducted to explore the relationships between medical burden, body mass index (BMI), substance use disorder status, and depressive symptom severity. Results: Of 225 patients enrolled, 41.8% had a recent substance use disorder, 50.7% were male, and 69.8% had bipolar I disorder. The mean age of the sample was 36.8 (SD = 10.8) years old. The mean number of comorbid medical disorders per patient was 2.5 (SD = 2.5), and the mean CIRS total score was 4.3 (SD = 3.1). A significant positive correlation was observed between baseline depression severity and the number of organ systems affected by medical illness (p = 0.04). Illnesses of the endocrine/metabolic system were inversely correlated with remission from depressive symptoms (p = 0.02), and obesity was specifically associated with poorer treatment outcome. For every 1-unit increase in BMI, the likelihood of response decreased by 7.5% [odds ratio (OR) = 0.93, 95% confidence interval (CI): 0.87– 0.99; p = 0.02] and the likelihood of remission decreased by 7.3% (OR = 0.93, 95% CI: 0.87–0.99; p = 0.03). The effect of comorbid substance use on the likelihood of response differed significantly according to baseline BMI. The presence of a comorbid substance use disorder resulted in lower odds of response, but only among patients with a BMI ≥ 23 (p = 0.02). Conclusion: Among patients with rapid-cycling bipolar disorder receiving lithium and valproate, endocrine/metabolic illnesses, including overweight and obesity, appear to be associated with greater depressive symptom severity and poorer treatment outcomes.Keywords
This publication has 55 references indexed in Scilit:
- Can body mass index help predict outcome in patients with bipolar disorder?Bipolar Disorders, 2009
- Medical and substance use comorbidity in bipolar disorderJournal of Affective Disorders, 2009
- Replicable differences in preferred circadian phase between bipolar disorder patients and control individualsPsychiatry Research, 2009
- The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis?Depression and Anxiety, 2009
- Depressive Symptoms and Metabolic Syndrome: Is Inflammation the Underlying Link?Biological Psychiatry, 2008
- Hypoinsulinemia Regulates Amphetamine-Induced Reverse Transport of DopaminePLoS Biology, 2007
- Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2007
- Association Between Obesity and Psychiatric Disorders in the US Adult PopulationArchives of General Psychiatry, 2006
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978